Acurx Pharmaceuticals Inc (ACXP) Stock Price, Quote & News

Company Profile

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant st...

Industry: Biotechnology

Sector: Healthcare

Phone: 917 533 1469

Website: www.acurxpharma.com

Address:

259 Liberty Avenue, Staten Island, United States

MarketForecasting Jul. 28 at 9:18 PM

$ACXP pharma tariffs should definitely benefit this small antibiotics company , forget about tariffs even for a second , national security reasons as well ,amongst other pro maga agenda priorities . It checks all the boxes for this current administration and acurx to work out a blockbuster deal that will secure America’s future for years to come .

0 · Reply

Pipelinepivots Jul. 28 at 6:10 PM

PRFX deal closing any day! Opioid-free pain relief is the future and PRFX is ahead of the curve. FDA-backed tech, low float, and huge unmet demand. One trial update or partner deal and this goes vertical. Nobody’s watching… I am. $ACXP $ENSC $QNRX

0 · Reply

sssssssssssssAhmed Jul. 28 at 5:43 PM

$ACXP delist soon

0 · Reply

Bonso99 Jul. 28 at 10:47 AM

$ACXP 💚

0 · Reply

walltr8der Jul. 28 at 10:43 AM

$ACXP

0 · Reply

Pharma_Stock_Calls Jul. 28 at 10:35 AM

✅ 💊 $ACXP Entry: $0.4060 → Target: $0.5426

0 · Reply

Ueberschlaefer Jul. 27 at 9:20 PM

$ACXP went ahead and ate the loss. some thoughts - TPST did the right thing by filing an 8-K announcing their attention to get bought out. they laid off their staff, paid off debt and converted a few execs to contractor roles. why? to get bought. their drug is derisked and out of integrity and respect for shareholders, they opted not to keep diluting shares by paying salaries when the drug was just too expensive to fund on their own thru a phase 3. they partnered with MTS and will eventually get bought. this company didn't do that. they are significantly derisked and even further along the road to sale. so what did they do? started blabbing about dilution, fucking shareholders who got them this far. it's really the height of ingratitude and american executive stupidity. they should've followed TPST before threatening investors with the destruction of the investment. make no mistake: RS is the utter and complete destruction of existing shareholder wealth. for the sake of what? to keep burning cash, keep people in salaries. the work is over for this company and it's time for BP to pick it up and get it over the finish line. retail has done its part.

0 · Reply

Bulltrader988 Jul. 25 at 7:45 PM

$ACXP Holding... Lets find out 👃👀

0 · Reply

sssssssssssssAhmed Jul. 25 at 7:34 PM

$ACXP 100 to one share splitting now. This means that it will drop down to 0.01

0 · Reply

Ueberschlaefer Jul. 25 at 7:26 PM

$ACXP OUT! i always make it back on the shorts though. will be back! this POS pops its head up after the RS, i will be here.

0 · Reply

Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update

Jun 17, 2025, 9:47 PM EDT - 5 weeks ago

Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds

Jun 17, 2025, 7:01 AM EDT - 5 weeks ago

Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI

Jun 9, 2025, 7:30 AM EDT - 7 weeks ago

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference

May 13, 2025, 1:59 PM EDT - 2 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:01 AM EDT - 2 months ago

Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update

Apr 30, 2025, 7:30 AM EDT - 3 months ago

Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

Apr 28, 2025, 7:30 AM EDT - 3 months ago

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Apr 17, 2025, 7:30 AM EDT - 3 months ago

Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Mar 18, 2025, 9:44 AM EDT - 4 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 7:01 AM EDT - 4 months ago

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 10, 2025, 4:30 PM EDT - 5 months ago

Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering

Mar 7, 2025, 8:00 AM EST - 5 months ago

Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering

Mar 3, 2025, 8:00 AM EST - 5 months ago

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

Feb 28, 2025, 8:00 AM EST - 5 months ago

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

Feb 24, 2025, 8:00 AM EST - 5 months ago

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

Feb 19, 2025, 8:00 AM EST - 5 months ago

JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors

Jan 7, 2025, 5:00 PM EST - 7 months ago

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 6, 2025, 5:35 PM EST - 7 months ago

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 6, 2025, 8:30 AM EST - 7 months ago

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

Dec 11, 2024, 11:00 AM EST - 8 months ago

Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

Dec 9, 2024, 8:00 AM EST - 8 months ago

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

Nov 20, 2024, 10:53 AM EST - 8 months ago

Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbook

Nov 20, 2024, 7:01 AM EST - 8 months ago

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

Nov 18, 2024, 7:00 AM EST - 9 months ago

Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update

Nov 13, 2024, 11:43 AM EST - 9 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:00 AM EST - 9 months ago

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

Oct 21, 2024, 10:07 AM EDT - 10 months ago

Acurx Ready To Expand Pipeline With Anthrax Treatment

Oct 21, 2024, 7:00 AM EDT - 10 months ago

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference

Oct 17, 2024, 8:00 AM EDT - 10 months ago

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement

Oct 16, 2024, 8:00 AM EDT - 10 months ago

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024

Oct 14, 2024, 1:00 PM EDT - 10 months ago

New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support

Oct 11, 2024, 10:50 AM EDT - 10 months ago

New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST

Sep 26, 2024, 7:00 AM EDT - 10 months ago

Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues

Sep 24, 2024, 7:00 AM EDT - 10 months ago

Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium

Aug 26, 2024, 7:00 AM EDT - 1 year ago

ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 10:20 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 7:01 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update

Jul 17, 2024, 7:00 AM EDT - 1 year ago

USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome

Jul 16, 2024, 7:00 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update

Jul 15, 2024, 7:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference

May 15, 2024, 1:14 PM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call Transcript

May 15, 2024, 9:00 AM EDT - 1 year ago

Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection

May 15, 2024, 7:00 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update

May 2, 2024, 7:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference

Apr 25, 2024, 10:12 AM EDT - 1 year ago

Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference

Apr 23, 2024, 10:57 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update

Mar 21, 2024, 7:01 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIV

Mar 18, 2024, 11:19 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcript

Mar 18, 2024, 7:01 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

MarketForecasting Jul. 28 at 9:18 PM

0 · Reply

Pipelinepivots Jul. 28 at 6:10 PM

0 · Reply

sssssssssssssAhmed Jul. 28 at 5:43 PM

$ACXP delist soon

0 · Reply

Bonso99 Jul. 28 at 10:47 AM

$ACXP 💚

0 · Reply

walltr8der Jul. 28 at 10:43 AM

$ACXP

0 · Reply

Pharma_Stock_Calls Jul. 28 at 10:35 AM

✅ 💊 $ACXP Entry: $0.4060 → Target: $0.5426

0 · Reply

Ueberschlaefer Jul. 27 at 9:20 PM

0 · Reply

Bulltrader988 Jul. 25 at 7:45 PM

$ACXP Holding... Lets find out 👃👀

0 · Reply

sssssssssssssAhmed Jul. 25 at 7:34 PM

$ACXP 100 to one share splitting now. This means that it will drop down to 0.01

0 · Reply

Ueberschlaefer Jul. 25 at 7:26 PM

$ACXP OUT! i always make it back on the shorts though. will be back! this POS pops its head up after the RS, i will be here.

0 · Reply

Ueberschlaefer Jul. 25 at 7:10 PM

$ACXP i agree. there's no point in remaining on the NQ unless the intent is to fuck investors who've been holding for some time. it's really a vicious thing to do to other human beings. the fate after the RS is the same = goes to sub $1 quickly. every shorter will end up here, piling on every day until it's worth nothing again. rinse, repeat. OTC is the better choice for investors. i'd rather that the fees they pay for an RS be used to hire MTS Partners or some other good firm to get a sale.

1 · Reply

Ueberschlaefer Jul. 25 at 7:05 PM

$ACXP i will sell at a loss. dilution for a biotech like this just means your shares go to a virtual zero. this is gonna hurt. this is why i don't hold biotechs much anymore.

0 · Reply

MarketForecasting Jul. 25 at 5:59 PM

$ACXP “blow them to smithereens”

0 · Reply

flcountryboy Jul. 25 at 4:51 PM

$ACXP - I d rather they go back to pink sheets while keeping SP the same , instead of RS just to stay on Nasdaq. The outcome of the ibez is same either way, and SP will be a result of success or failure. Its current SHs that will be screwed if RS is inacted...

0 · Reply

flcountryboy Jul. 25 at 4:41 PM

$ACXP i must admit... special meeting to notify SHs of reverse split is disheartening and probably means ibez is no closer to anything of significance which would positively affect the SP. I am tempted to take my loss now rather wait till RS action increases my loss. Every company i have been in with RS is in just as bad a shape as presplit 6 months later, or sooner. Very upsetting....

2 · Reply

iWasBornYesterday Jul. 25 at 4:08 PM

$ACXP Betch is not delist maybe a reverse split. Stfu!

1 · Reply

iWasBornYesterday Jul. 25 at 4:05 PM

$ACXP Reverse split is happening. WTF!

0 · Reply

sssssssssssssAhmed Jul. 25 at 3:16 PM

$ACXP plan to delist now

1 · Reply

finallyfree22 Jul. 25 at 3:07 PM

$ACXP

1 · Reply

walltr8der Jul. 25 at 11:54 AM

$ACXP Cheap Safe Effective=Ibezapolstat

1 · Reply

iWasBornYesterday Jul. 25 at 12:10 AM

$ACXP Reverse split is coming soon. Drop the price now. 😂

0 · Reply

iWasBornYesterday Jul. 24 at 7:52 PM

$ACXP Short it this ceo is an ass h0le.

4 · Reply

Market Cap	12.03M
Revenue (ttm)	0.00
Net Income (ttm)	-14.10M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	614,100
Avg Vol	7,772,543
Day's Range	N/A - N/A
Shares Out	29.63M
Stochastic %K	6%
Beta	-1.23
Analysts	Strong Sell
Price Target	$4.83